Wegovy and POTS: separating the concern from the noise

The myth: Wegovy is simply off-limits for people with POTS

This is the claim that circulates most persistently in POTS communities online, and it needs correcting. The Wegovy SmPC does not list POTS as a contraindication. No major UK prescribing authority (the MHRA, NICE or the NHS) has issued a blanket restriction on semaglutide use in people with autonomic conditions. What the evidence does show, and what the NHS patient information for semaglutide flags clearly, is that heart rate changes and dehydration are real considerations that deserve careful management. That is a different thing from a prohibition.

The confusion is understandable. POTS patients are, rightly, cautious about anything that touches heart rate or blood pressure regulation. And some prescribers unfamiliar with POTS will decline rather than assess, which is frustrating but not the same as the medicine being clinically ruled out. The right question is not "is Wegovy banned for POTS?" but "what does the risk-benefit picture look like for this specific patient?" That requires a prescriber who knows both conditions.

Getting a clear, honest answer to this question is one reason a thorough consultation matters. At nume, every application is read by a named GPhC-registered prescriber, not passed through an automated filter, so complex histories get the attention they deserve.

What semaglutide actually does to heart rate, and why it matters for POTS

In the STEP 1 trial, published in the New England Journal of Medicine, semaglutide 2.4mg produced an average resting heart rate increase of around one to two beats per minute over 68 weeks. That is a small number for most people. For someone with POTS, whose heart rate may already leap 30 or more beats per minute on standing, even a modest upward nudge at rest could shift the baseline in an unwanted direction. It does not mean treatment is impossible, but it does mean monitoring is more important than usual.

The mechanism behind this effect is not fully established. GLP-1 receptors exist in cardiac tissue, and semaglutide's autonomic effects appear to involve both central and peripheral pathways. None of this is unique to POTS, but it is more consequential when baseline autonomic regulation is already impaired. A practical habit worth building: note your resting heart rate in the morning before you get up, once a week, during the titration period. One minute, lying still, before you stand. It gives you and your prescriber something concrete to track.

If you are thinking about the broader landscape of GLP-1 treatments, the semaglutide overview sets out how this class of medicine works and what separates the individual products.

The dehydration risk: the POTS complication that deserves more attention

This is the concern our prescribers hear least often, and arguably the most practically important one. Nausea, vomiting and diarrhoea are among the most common early side effects of Wegovy shots, particularly during dose escalation. For most people, these settle within a couple of weeks at each new dose. For someone with POTS, even mild dehydration can trigger a significant symptomatic flare: worsening orthostatic intolerance, increased heart rate on standing, lightheadedness and fatigue.

The implication is not to avoid Wegovy but to take the titration schedule seriously, maintain fluid and sodium intake scrupulously during any GI upset, and have a clear plan agreed with your POTS clinician before starting. The guidance on how Wegovy injections are taken covers the dose escalation pathway that every patient follows. Slow titration is standard anyway; in a POTS context it becomes non-negotiable.

If dehydration from GI side effects becomes severe, seek medical advice promptly. This is not a "push through it" situation for someone with autonomic dysfunction. The NHS semaglutide page recommends contacting a healthcare professional if vomiting or diarrhoea leads to signs of dehydration, pale, clammy skin, rapid heartbeat, reduced urine output.

Getting this right: what a responsible assessment looks like

For most weight-management conditions, a standard clinical questionnaire captures the relevant history. POTS sits in a slightly different category because it intersects with cardiology, neurology and sometimes rheumatology, depending on the underlying cause. A prescriber assessing someone with POTS for Wegovy weight loss shots should know the current POTS treatment regimen, understand whether beta-blockers or fludrocortisone are in use (both can interact with the haemodynamic changes semaglutide produces), and have a view on symptom severity and stability.

This is also where cost context becomes relevant. If you are weighing up the investment involved in private treatment, the Wegovy price guide explains what the market looks like honestly. A service that does this well is worth what it charges; one that waves complex histories through without proper scrutiny is not.

The NICE appraisal of semaglutide for weight management (TA875) sets out the population for whom treatment is recommended and emphasises the role of a multidisciplinary clinical assessment, exactly the standard that makes a difference when a condition like POTS is part of the picture. If you have questions after reading this, our clinical team is reachable at the contact page, and a full consultation (where you can describe your history in detail) starts at the weight-loss treatments page.